Pancreatic cancer remains one of the most challenging malignancies, with a five-year survival rate of just 13% in the United States as of 2026. Outcomes, however, are not uniform. Survival depends heavily on the stage at diagnosis, the patient’s age, gender, geographic location, and whether treatment is received. Understanding these differences helps patients, families, and clinicians frame realistic expectations and identify opportunities for earlier detection and more effective care.
Progress has been slow but steady. Over the past five decades, the five-year survival rate has climbed from around 6% in the 1970s to the current 13%, according to the Pancreatic Cancer Action Network. Still, pancreatic cancer has the lowest survival rate of any major cancer, largely because most cases are diagnosed at an advanced stage when curative surgery is no longer possible.
Pancreatic cancer survival rates by age
13%
Overall 5‑year survival (US, 2026)
PanCAN.org
~10%
1‑year survival (all stages, UK)
Cancer Research UK
3.2%
Stage IV 5‑year survival
Johns Hopkins Medicine
~44%
Stage I localized 5‑year survival
American Cancer Society
Key insights
- Pancreatic cancer has the lowest 5‑year survival rate among major cancers, but rates have improved from about 6% in the 1970s to 13% in 2026.
- Survival drops dramatically with advanced stage: localized disease carries a ~44% 5‑year survival, while distant stage drops to ~3%.
- Age is a significant factor: patients under 45 have 3–4 times higher survival than those over 75.
- Gender differences are minimal in most studies; women may have a slight advantage, but the effect is small.
- Without treatment, median survival for advanced disease is 2–4 months.
| Category | Statistic | Source |
|---|---|---|
| Overall 5‑year survival (US, 2026) | 13% | PanCAN (SEER data) |
| Overall 5‑year survival (UK) | ~7% | Cancer Research UK (2016‑2020) |
| Stage I localized | ~44% | American Cancer Society (SEER) |
| Stage IV distant | 3.2% | Johns Hopkins Medicine |
| Median survival, stage IV | ~11 months | Johns Hopkins / PanCAN |
| 1‑year survival (all stages, UK) | ~10% | Cancer Research UK |
| Survival without treatment (advanced) | 2–4 months median | Palliative care studies |
Stage 4 pancreatic cancer survival rate by age
For metastatic (stage IV) disease, the five‑year survival rate is around 3% overall. Younger patients—those under 50—may have slightly better outcomes, but the difference is small. A peer‑reviewed study found that age itself is not the primary driver; instead, treatment tolerance and the ability to undergo aggressive therapy play a larger role. Once the cancer has spread, survival remains poor regardless of age.
Stage 1 pancreatic cancer survival rate by age
When pancreatic cancer is caught at stage I and surgically removed, survival improves substantially. The American Cancer Society reports a 44% five‑year survival for localized disease. Age still matters: younger patients (under 65) are more likely to be candidates for surgery and can achieve five‑year survival rates above 50% in some series. For patients over 75, comorbidities and reduced surgical tolerance lower these figures.
Pancreatic cancer survival rate at 80 years old
National Cancer Institute data, cited by Medical News Today, indicate that people aged 75 and older have a 5.3% relative five‑year survival rate. For an 80‑year‑old, the outlook is influenced more by overall health and stage at diagnosis than by age alone. Many older patients are unable to tolerate aggressive surgery or chemotherapy, which can further reduce survival.
Younger patients survive longer on average, but much of that advantage comes from being more likely to receive surgery and tolerate chemotherapy. Stage at diagnosis remains the dominant factor. A healthy 80‑year‑old diagnosed with stage I disease may have a better outlook than a 50‑year‑old with stage IV cancer.
Stage‑specific pancreatic cancer survival rates
The stage at which pancreatic cancer is discovered is the single strongest predictor of survival. The American Cancer Society, using SEER data from 2015–2021, reports the following five‑year relative survival rates:
- Localized (confined to the pancreas): 44%
- Regional (spread to nearby lymph nodes or tissues): 17%
- Distant (metastatic to other organs): 3%
Johns Hopkins Medicine provides a slightly lower figure for stage IV: 3.2% five‑year survival. For very early stage (IA) tumors that can be completely removed, some studies report five‑year survival exceeding 80%. However, only 15% to 20% of pancreatic cancers are diagnosed at a stage where surgery is an option.
Why stage matters more than other factors
Once the cancer has spread beyond the pancreas, the chance of long‑term survival drops to the low single digits. Stage IV patients who receive treatment have a median survival of about 11 months, according to PanCAN and Johns Hopkins. Without treatment, median survival falls to 2–4 months.
Pancreatic tumors that can be surgically removed (resectable) offer the best chance for prolonged survival. PanCAN states that diagnosing pancreatic cancer in time for surgery can increase survival by more than ten‑fold. Stage IA patients may have a five‑year survival rate above 80% in some datasets.
Pancreatic cancer survival rate in women
Evidence points to a modest survival advantage for women compared with men, but the difference is small and of limited clinical significance. A peer‑reviewed study of metastatic pancreatic cancer found a median overall survival of 2.3 months for women and 2.1 months for men—a difference of roughly 0.3 months that was not statistically significant in raw comparisons.
The same study noted that women received systemic treatment slightly less often overall (26% vs. 28%). Among patients aged 55 and under, however, women were more likely to receive therapy. The authors concluded that sex‑based differences are likely driven by treatment allocation, age distribution, disease biology, and access to care rather than by gender alone.
While some analyses suggest a slight survival benefit for women, official bodies like the American Cancer Society and Cancer Research UK do not report separate survival rates by sex. Any advantage is outweighed by the effects of stage and treatment eligibility.
Pancreatic cancer survival rate UK
In the United Kingdom, survival statistics are compiled by Cancer Research UK based on data for England and Wales. The agency reports that 25% of patients survive for one year or more, more than 5% survive for five years or more, and around 5% survive for ten years or more.
The UK five‑year survival rate (around 7%) is lower than the US rate (13%). This gap likely reflects differences in stage at diagnosis, treatment access, population health, and the time periods used in registry data. Even within the UK, survival varies by region, socioeconomic status, and proximity to high‑volume pancreatic surgery centers.
Pancreatic cancer survival rate without treatment
For patients who do not receive any cancer‑directed therapy, survival is very poor. In advanced (metastatic) pancreatic cancer, median survival without treatment is 2 to 4 months. For early‑stage disease that is not surgically removed, survival may be slightly longer but still measured in months.
These figures are drawn from older studies and palliative care cohorts. Modern supportive care, including pain management and nutritional support, may extend life modestly, but the underlying prognosis remains grave without active anticancer treatment.
Pancreatic cancer survival rate by year
The five‑year survival rate has improved gradually over the past five decades. According to PanCAN and SEER data:
- 1970s: ~5–6%
- 1990s: ~8%
- 2010s: ~10%
- 2020: ~12%
- 2026 (current): 13%
The improvement reflects advances in surgical techniques, the introduction of gemcitabine in the 1990s, the FOLFIRINOX regimen in the 2010s, and the emergence of targeted therapies and immunotherapies in recent years. Still, progress remains slow compared with other cancers.
How has pancreatic cancer survival changed over time?
- 1970s: Five‑year survival around 5–6%. Limited treatment options, mostly late diagnosis.
- 1990s: Survival improves to about 8%. Better surgical techniques and introduction of gemcitabine.
- 2010s: Survival reaches approximately 10%. FOLFIRINOX regimen improves outcomes in fit patients.
- 2020: Survival rises to around 12%. Targeted therapies and immunotherapy under trial.
- 2026 (current): Five‑year survival reported at 13% by PanCAN, based on SEER data.
What the statistics really mean – certainty vs. uncertainty
Population‑level survival rates are reliable because they are derived from large cancer registries such as SEER in the United States and national registries in the UK. For example, stage I patients who undergo surgical resection have a five‑year survival rate of 50–60% in some series. These figures are well established.
However, individual prognosis remains highly uncertain. Survival rates are historical averages and may not reflect recently approved therapies or individual tumor biology. Age‑specific data often group patients into broad bands (e.g., 60–74), masking variation within those groups. Survival estimates without treatment are based on small, older studies, and modern palliative care may modestly extend life.
Established: Population-level survival rates are trustworthy; surgical resection dramatically improves outcomes.
Uncertain: Individual prognosis varies widely; historical rates may not reflect new drugs; age bands are broad.
Why are pancreatic cancer survival rates so low?
Several factors contribute to the poor prognosis:
- Late diagnosis: About 80% of cases are diagnosed at an advanced stage when surgery is no longer possible.
- Aggressive tumor biology: Pancreatic cancers grow rapidly, metastasize early, and resist chemotherapy.
- Limited screening: No routine screening exists for average‑risk individuals.
- Vague symptoms: The pancreas is deep in the abdomen; early signs such as jaundice or weight loss often appear only after the disease is advanced.
Expert sources and official data
“As of January 2026, the five‑year survival rate for pancreatic cancer is 13%.”
— Pancreatic Cancer Action Network (PanCAN)
“Around 10 out of 100 people (10%) survive for 1 year after diagnosis. Only 1% survive for 3 years.”
— Cancer Research UK
“The 5‑year survival rate for localized pancreatic cancer is 44%, for regional 15%, for distant 3%.”
— American Cancer Society
“Stage IV pancreatic cancer has a five‑year survival rate of 3.2%.”
— Johns Hopkins Medicine
Key takeaways
Survival statistics help frame expectations, but each patient’s path is unique. Early detection remains critical—symptoms such as jaundice, unexplained weight loss, and abdominal pain warrant prompt medical evaluation. Clinical trials offer access to emerging therapies that may improve outcomes. For personalized support, organizations like PanCAN, Cancer Research UK, and the NHS provide clinical trial matching and counseling. For more details on related health risks, see Right Bundle Branch Block – Causes, Symptoms, and Life Expectancy and Can Sleep Apnea Kill You – Risks, Signs & Treatments.
Frequently Asked Questions
Is the survival rate different for men vs women?
Some studies suggest a slight survival advantage for women, but when adjusted for age and stage, differences are minimal. No official consensus exists.
What is the survival rate for pancreatic cancer in the UK compared to the US?
UK 5‑year survival is around 7%, while US is 13%. Differences are partly due to later diagnosis in the UK and different data collection periods. More recent data may narrow the gap.
How long can someone live with pancreatic cancer without treatment?
For advanced pancreatic cancer, median survival without treatment is 2–4 months. For early‑stage without surgery, survival may be slightly longer but still poor.
What is the overall 5‑year survival rate for pancreatic cancer?
As of 2026, the overall 5‑year relative survival rate is 13% in the United States, according to PanCAN.
Does age affect pancreatic cancer survival?
Yes, but age is less important than stage and treatment eligibility. Younger patients often have better outcomes because they are more likely to receive aggressive therapy.
Can stage I pancreatic cancer be cured?
Surgical removal offers the best chance. Five‑year survival for localized disease is about 44%, and for very early stage IA tumors it may exceed 80%.
What causes the low survival rate for pancreatic cancer?
Late diagnosis (80% advanced), aggressive tumor biology, lack of routine screening, and vague early symptoms are the main reasons.
Has the survival rate improved over time?
Yes, from about 6% in the 1970s to 13% in 2026, due to better surgery, chemotherapy regimens, and targeted therapies.
Victoria Winslow is Editor-in-Chief at ShowbizUK.co.uk, overseeing editorial policy, corrections, editorial standards, publication decisions, source review and content quality across the publication.